Primary central nervous system recurrence after paclitaxel therapy for epithelial ovarian malignancy.

Abstract

Paclitaxel is currently being utilized to treat neoplasms which have a significant incidence of central nervous system metastases. It is, however, unclear as to whether paclitaxel crosses the blood-brain barrier. In this report, the authors describe a patient with refractory epithelial ovarian cancer treated with paclitaxel at 135 mg/m2/24 hr every 21 days. The patient achieved a complete clinical response of all abdominal and pelvic disease, but simultaneously developed central nervous system metastases. Paclitaxel was effective against the patient's abdominal and pelvic disease but was not protective against central nervous system metastasis.

• Authors: V L Seewaldt, D C Figge, B E Greer, H K Tamimi, W S Brown, J M Cain
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 55 Issue 3 Pt 1 Pg. 456-8 (Dec 1994) ISSN: 0090-8258 [Print] United States
• PMID: 7835788 (Publication Type: Case Reports, Journal Article)

Chemical References

• Paclitaxel

Topics

• Central Nervous System Neoplasms (secondary)
• Cystadenocarcinoma, Serous (drug therapy, secondary)
• Female
• Humans
• Middle Aged
• Ovarian Neoplasms (drug therapy, pathology)
• Paclitaxel (therapeutic use)
• Recurrence
• Remission Induction